Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05694169 · ClinicalTrials.gov registry record · Phase 1
A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
A Phase 1 study, sponsored by Prokidney.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05694169 is a Phase 1 study that was terminated before completion, run by Prokidney. The registered enrollment target is 1 participants.
The verdict
NCT05694169, a Phase 1 study, was terminated before completion, sponsored by Prokidney.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2024-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05694169
The ClinicalTrials.gov registry entry for NCT05694169 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prokidney, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT05694169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05694169 about?
NCT05694169 is a clinical study titled "A Study of Participants With Chronic Kidney Disease Previously Treated With REACT". The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
What is the current status of trial NCT05694169?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2023-07-11. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT05694169?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05694169?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.